Cresco Labs Proving Not All Cannabis Stocks Are Sinking
Investing.com | Nov 24, 2020 11:07
Everyone generally accepts that what goes up eventually comes down. But the law of physics has nothing on the cannabis sector. The trend in the world of marijuana stocks has generally followed a slightly different pattern. When it comes to pot stocks, what goes up comes down, and then drops again.
But every so often—even in the cannabis sector—there is the exception that proves the rule. In this instance, that exception might just be Cresco Labs (OTC:CRLBF), (CSE:CL).
The Chicago-based marijuana grower is setting its own trajectory. In 2020, the stock has gained about 31.5%. And the prospects in the near-term are for more of the same.
Last week, Cresco Labs revealed its third-quarter results, which further bolstered its stock, with a one-day gain of about 8%. The company posted an adjusted EBITDA of US$46.3 million, well above twice what analysts were expecting.
Revenues for the quarter were also impressive. They totaled US$153.3 million, setting a new company record. The figure was about 63% higher than the previous quarter, and represented the third consecutive quarter with revenue growth that topped 40%.
Retail revenues were up 60% for the three-month period that ended Sept. 30, hitting US$62.8 million.
“Cresco Labs entered the third quarter firing on all cylinders, achieving record levels of revenue, profitability and cash flow. We remain the number one operator in the industry focused on, and delivering results in, the wholesale distribution of branded products,” said company co-founder and CEO Charles Bachtell.
“Our retail is outperforming, and we are generating substantial operating leverage.”
The company also posted strong results in its wholesale sales, generating US$90 million in revenues.
After the results were released, Altacorp Capital raised its target price for Cresco Labs to $14. It had previously been at $12.50.
Yesterday, shares of Cresco Labs closed at $9.02, up another 2.82% on the day.
h2 Tilray Fails To Deliver Turnaround/h2Canadian-based Tilray (NASDAQ:TLRY) continues to struggle, with its stock dipping back down after posting its latest earnings report earlier this month.
On Nov. 9, the pharmaceutical cannabis company reported $51.41 million during the quarter, compared to analysts' expectations of $54.91 million. Its revenue for the quarter was up 0.6% compared with the same quarter last year. The news propelled the stock to just over $11 a share before investors backed off.
Get The App
Yesterday, the stock closed at $6.68, down almost 40% in the past two weeks. In the last year, Tilray stock has lost over 68.5%
What goes down, sometimes keeps going down in the cannabis sector.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.